Abbott, CamDiab naYpsomed nhasi vazivisa kuti vari kudyidzana kugadzira nekutengesa yakasanganiswa automated insulin delivery (AID) system yekubatsira kudzikisira mutoro wekutenderera-wachi-kweshe kwekutonga kwechirwere cheshuga kuvanhu vane chirwere cheshuga. Iko kutarisisa kwekutanga kwemubatanidzwa kuchave munyika dzeEurope.

Iyo itsva yakabatanidzwa AID sisitimu iri kugadzirwa kubatanidza Abbott's FreeStyle Libre® 3 sensor, idiki pasirese1 uye yakanyatsojeka2,3 inoenderera glucose yekutarisa sensor ine kuverenga miniti yega yega, kuCamDiab's CamAPS FX mobile app, inobatanidza neYpsomed's mylife™ YpsoPump® - kugadzira yakangwara, otomatiki maitiro ekuendesa insulin yakavakirwa pane chaiyo-nguva data yeglucose. Iyo yakabatana, yakangwara inopfeka mhinduro yakagadzirirwa kuenderera mberi nekutarisa mazinga eglucose emunhu uye kugadzirisa otomatiki uye kuunza huwandu hwakakodzera hwe insulin panguva chaiyo, kubvisa fungidziro ye insulin dosing.

"Chinangwa chedu ndechekuita kuti kurapwa kwechirwere cheshuga kuve nyore sezvinobvira, ndosaka Abbott achienderera mberi nekuwedzera timu yake yevanotakura insulin, vadzidzisi vedhijitari uye vatungamiriri vetekinoroji," akadaro Jared Watkin, mutevedzeri wemutungamiri webhizinesi rekuchengeta chirwere cheshuga chaAbbott. "Tinoda kuunza mhinduro nyowani dzepamberi dzinorerutsa uye kuita kuti vanhu vapedze nguva shoma vachifunga nezvechirwere cheshuga uye nguva yakawanda yekurarama."

“Kutadza kudzora shuga kunoita kuti pave nenjodzi yakawedzerwa yechirwere cheshuga senge upofu, uye chirwere chemoyo neitsvo. Tinoda kubatsira vanhu vane chirwere cheshuga kubata zvakanaka glucose yavo kuburikidza nehunyanzvi hwepamusoro. Yedu CamAPS FX, yakatotenderwa kuEurope, inogadzirisa algorithm iyo kana yakabatanidzwa neAbbott's sensor iri kugadzirwa kuti itaurirane neYpsomed's insulin pump kuti ipe iyo yakakwana insulin dosi, kusimudza mutoro wekugadzirisa mamiriro ayo asingaregi kufungidzira siku nesikati. ", akadaro Roman Hovorka, director weCamDiab Ltd.

“Tine chokwadi chekuti matambudziko makuru munharaunda anogona kugadziriswa chete kuburikidza nekudyidzana. Naizvozvo tinodada nekuwedzera vatinoshanda navo uye kubatana kuti tipe rusununguko rwakawanda rwekusarudza mukugadzirisa chirwere cheshuga. Kana yasanganiswa mylife ™ YpsoPump® neFreeStyle Libre 3 system uye CamAPS FX advanced adaptive hybrid yakavharwa-loop app, tichakwanisa kuendesa imwe compact uye lightweight AID system inonzwisisika uye iri nyore kushandisa, "akadaro Simon Michel. mukuru mukuru weYpsomed.

Iwo makambani anotarisira kupedzisa kusimudzira mukupera kwa2022 nekuwanikwa kwekutengesa kunotarisirwa ipapo.

ZVOKUBVA MUNYAYA INO:

Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night,”.
The new integrated AID system is being designed to connect Abbott’s FreeStyle Libre® 3 sensor, the world’s smallest1 and most accurate2,3 continuous glucose monitoring sensor with readings every minute, to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife™ YpsoPump® – creating a smart, automated process to deliver insulin based on real-time glucose data.
When combined our mylife™ YpsoPump® with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use,”.